Quest Diagnostics, Myriad Genetics End BRCA Gene-patent Litigation - Quick Facts

(RTTNews) - Quest Diagnostics (DGX),a provider of diagnostic information services, and Myriad Genetics Inc. (MYGN) have reached a deal that ends their BRCA gene-patent litigation.

As part of the agreement, Quest Diagnostics and Myriad Genetics and its co-parties in the litigation, the University of Utah Research Foundation, the Trustees of the University of Pennsylvania, HSC Research and Development Limited Partnership, and Endorecherche, Inc. dismiss their lawsuits, claims, counterclaims and disputes related to Myriad's patent claims on BRCA1 and BRCA2 in the litigation.

Also, Myriad provided Quest Diagnostics and its physician, hospital and other customers and business partners a covenant not to sue with respect to the patents at issue.

In October 2013, Quest Diagnostics launched BRCAvantage, a suite of next-generation sequencing services that help identify genetic risk for breast and ovarian cancer based on mutations in the BRCA1 and BRCA2 genes.